|
Market Closed -
Japan Exchange
09:30:00 28/10/2026 +03
|
5-day change | 1st Jan Change | ||
| 6,307.00 JPY | -1.56% |
|
-0.05% | +30.44% |
| 10-26 | Takeda Pharmaceutical Eyes 2027 Japan Filing for Gastric Cancer Treatment | MT |
| 10-25 | Takeda to seek Japan approval for gastric cancer drug next year | RE |
Company Valuation: Takeda Pharmaceutical Company Limited
Data adjusted to current consolidation scope
| Fiscal Period: March | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 5,423,454 | 6,762,204 | 6,564,378 | 6,749,675 | 8,948,061 | 10,070,757 | - | - |
| Change | - | 24.68% | -2.93% | 2.82% | 32.57% | 12.55% | - | - |
| Enterprise Value (EV) 1 | 8,919,170 | 10,611,015 | 10,950,330 | 10,725,175 | 5,130,461 | 13,978,160 | 13,775,544 | 13,471,149 |
| Change | - | 18.97% | 3.2% | -2.06% | -52.16% | 172.45% | -1.45% | -2.21% |
| P/E | 23.8x | 21.3x | 45.4x | 64.6x | 46.4x | 50.8x | 32.2x | 26.2x |
| PBR | 0.95x | 1.06x | 0.9x | 1x | 1.2x | 1.37x | 1.37x | 1.36x |
| PEG | - | 0.5x | -0.8x | -2.5x | 0.6x | 14.67x | 0.6x | 1.1x |
| Capitalization / Revenue | 1.52x | 1.68x | 1.54x | 1.47x | 1.99x | 2.14x | 2.1x | 2.04x |
| EV / Revenue | 2.5x | 2.63x | 2.57x | 2.34x | 1.14x | 2.97x | 2.87x | 2.74x |
| EV / EBITDA | 8.54x | 9.19x | 11.6x | 9.71x | 4.54x | 10.9x | 9.95x | 9.32x |
| EV / EBIT | 19.4x | 21.6x | 51.1x | 31.3x | 12.6x | 29.7x | 22.8x | 19.3x |
| EV / FCF | 8.92x | 28.7x | 43.4x | 15.5x | 8.14x | 19.8x | 19.7x | 18.3x |
| FCF Yield | 11.2% | 3.49% | 2.31% | 6.43% | 12.3% | 5.04% | 5.09% | 5.45% |
| Dividend per Share 2 | 180 | 180 | 188 | 196 | 200 | 204.3 | 208.4 | 215.8 |
| Rate of return | 5.15% | 4.14% | 4.49% | 4.44% | 3.53% | 3.19% | 3.25% | 3.37% |
| EPS 2 | 147.1 | 204.3 | 92.09 | 68.36 | 122 | 126.2 | 198.9 | 244.4 |
| Distribution rate | 122% | 88.1% | 204% | 287% | 164% | 162% | 105% | 88.3% |
| Net sales 1 | 3,569,006 | 4,027,478 | 4,263,762 | 4,581,600 | 4,505,700 | 4,701,837 | 4,795,879 | 4,925,220 |
| EBITDA 1 | 1,043,995 | 1,154,905 | 942,077 | 1,103,982 | 1,129,888 | 1,283,280 | 1,384,870 | 1,445,085 |
| EBIT 1 | 460,844 | 490,505 | 214,100 | 342,600 | 408,800 | 469,869 | 603,713 | 699,373 |
| Net income 1 | 230,059 | 317,017 | 144,067 | 107,900 | 191,800 | 196,331 | 323,029 | 384,410 |
| Net Debt 1 | 3,495,716 | 3,848,811 | 4,385,952 | 3,975,500 | -3,817,600 | 3,907,403 | 3,704,786 | 3,400,392 |
| Reference price 2 | 3,498.00 | 4,350.00 | 4,184.00 | 4,413.00 | 5,664.00 | 6,407.00 | 6,407.00 | 6,407.00 |
| Nbr of stocks (in thousands) | 1,550,444 | 1,554,530 | 1,568,924 | 1,529,498 | 1,579,813 | 1,596,759 | - | - |
| Announcement Date | 5/11/22 A | 5/11/23 A | 5/9/24 A | 5/8/25 A | 5/13/26 A | - | - | - |
1JPY in Million2JPY
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 50.76x | 3.01x | 11.02x | 3.19% | 64.8B | |
| 37.66x | 13.18x | 27.98x | 0.53% | 1,143B | |
| 39.33x | 6.61x | 18.6x | 1.99% | 647B | |
| 37.45x | 8.4x | 17.37x | 2.4% | 506B | |
| 21.46x | 5.22x | 12.98x | 2.51% | 384B | |
| 103.38x | 5.8x | 24.86x | 2.4% | 350B | |
| 21.99x | 5.69x | 13.69x | 2.94% | 293B | |
| 22.31x | 4.51x | 12.87x | 1.96% | 265B | |
| 28.42x | 7.28x | 13.03x | 2.25% | 242B | |
| -45.78x | 7.1x | 27.53x | 2.07% | 197B | |
| Average | 31.70x | 6.68x | 17.99x | 2.22% | 409.23B | |
| Weighted average by Cap. | 35.52x | 8.27x | 20.33x | 1.82% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- 4502 Stock
- Valuation Takeda Pharmaceutical Company Limited
Select your edition
All financial news and data tailored to specific country editions
